RU2012114097A - Терапевтический агент против хронической боли - Google Patents
Терапевтический агент против хронической боли Download PDFInfo
- Publication number
- RU2012114097A RU2012114097A RU2012114097/15A RU2012114097A RU2012114097A RU 2012114097 A RU2012114097 A RU 2012114097A RU 2012114097/15 A RU2012114097/15 A RU 2012114097/15A RU 2012114097 A RU2012114097 A RU 2012114097A RU 2012114097 A RU2012114097 A RU 2012114097A
- Authority
- RU
- Russia
- Prior art keywords
- chronic pain
- aripiprazole
- therapeutic agent
- agent against
- patient
- Prior art date
Links
- 208000000094 Chronic Pain Diseases 0.000 title claims abstract 13
- 208000002193 Pain Diseases 0.000 title claims abstract 13
- 239000003814 drug Substances 0.000 title claims abstract 9
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract 9
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims abstract 12
- 229960004372 aripiprazole Drugs 0.000 claims abstract 12
- 238000000034 method Methods 0.000 claims abstract 4
- 239000002253 acid Substances 0.000 claims abstract 2
- 230000037396 body weight Effects 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 239000012453 solvate Substances 0.000 claims abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
1. Терапевтический агент против хронической боли, содержащий арипипразол в качестве активного компонента.2. Терапевтический агент против хронической боли по п.1, который содержит арипипразол или его аддитивную соль кислоты или сольват в качестве активного компонента.3. Терапевтический агент против хронической боли по п.1 или п.2, дополнительно содержащий фармацевтически приемлемый носитель.4. Применение арипипразола для производства терапевтического агента против хронической боли.5. Применение арипипразола для лечения хронической боли.6. Способ лечения хронической боли, включающий введение эффективного количества арипипразола пациенту.7. Способ по п.6, в котором арипипразол вводят пациенту в виде суточной дозы примерно от 0,05 до 10 мг на кг массы тела.
Claims (7)
1. Терапевтический агент против хронической боли, содержащий арипипразол в качестве активного компонента.
2. Терапевтический агент против хронической боли по п.1, который содержит арипипразол или его аддитивную соль кислоты или сольват в качестве активного компонента.
3. Терапевтический агент против хронической боли по п.1 или п.2, дополнительно содержащий фармацевтически приемлемый носитель.
4. Применение арипипразола для производства терапевтического агента против хронической боли.
5. Применение арипипразола для лечения хронической боли.
6. Способ лечения хронической боли, включающий введение эффективного количества арипипразола пациенту.
7. Способ по п.6, в котором арипипразол вводят пациенту в виде суточной дозы примерно от 0,05 до 10 мг на кг массы тела.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009211021 | 2009-09-11 | ||
| JP2009-211021 | 2009-09-11 | ||
| PCT/JP2010/053032 WO2011030575A1 (ja) | 2009-09-11 | 2010-02-26 | 慢性疼痛治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2012114097A true RU2012114097A (ru) | 2013-10-20 |
| RU2555760C2 RU2555760C2 (ru) | 2015-07-10 |
Family
ID=43732252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012114097/15A RU2555760C2 (ru) | 2009-09-11 | 2010-02-26 | Терапевтический агент против хронической боли |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20120258971A1 (ru) |
| JP (2) | JPWO2011030575A1 (ru) |
| KR (2) | KR20120065392A (ru) |
| AU (1) | AU2010293647B2 (ru) |
| BR (1) | BR112012005401A2 (ru) |
| CA (1) | CA2773253A1 (ru) |
| CO (1) | CO6531434A2 (ru) |
| IL (1) | IL218495A0 (ru) |
| MX (1) | MX2012002952A (ru) |
| MY (1) | MY162348A (ru) |
| NZ (1) | NZ599227A (ru) |
| RU (1) | RU2555760C2 (ru) |
| SG (1) | SG178938A1 (ru) |
| TW (1) | TWI465442B (ru) |
| UA (1) | UA108862C2 (ru) |
| WO (1) | WO2011030575A1 (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| EP3468540A4 (en) * | 2016-06-13 | 2020-03-18 | Board Of Regents Of the University Of Texas System | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING PAIN |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54130587A (en) | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| US5006528A (en) * | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| JP2608788B2 (ja) * | 1988-10-31 | 1997-05-14 | 大塚製薬 株式会社 | 精神***病治療剤 |
| RU2259366C2 (ru) * | 2001-09-25 | 2005-08-27 | Оцука Фармасьютикал Ко., Лтд. | Арипипразоловое лекарственное средство с низкой гигроскопичностью и способы его получения |
| WO2004047841A1 (en) * | 2002-11-26 | 2004-06-10 | Alexza Molecular Delivery Corporation | Treatment of headache with antipsychotics delivered by inhalation |
| EP1797039A1 (en) * | 2004-09-13 | 2007-06-20 | Matrix Laboratories Ltd | Process for the preparation of polymorphs, solvates of aripiprazole using aripiprazole acid salts |
-
2010
- 2010-02-26 JP JP2011530759A patent/JPWO2011030575A1/ja active Pending
- 2010-02-26 RU RU2012114097/15A patent/RU2555760C2/ru not_active IP Right Cessation
- 2010-02-26 UA UAA201204551A patent/UA108862C2/uk unknown
- 2010-02-26 CA CA2773253A patent/CA2773253A1/en not_active Abandoned
- 2010-02-26 TW TW099105621A patent/TWI465442B/zh not_active IP Right Cessation
- 2010-02-26 US US13/395,364 patent/US20120258971A1/en not_active Abandoned
- 2010-02-26 SG SG2012014569A patent/SG178938A1/en unknown
- 2010-02-26 WO PCT/JP2010/053032 patent/WO2011030575A1/ja active Application Filing
- 2010-02-26 KR KR1020127009183A patent/KR20120065392A/ko active IP Right Grant
- 2010-02-26 AU AU2010293647A patent/AU2010293647B2/en not_active Ceased
- 2010-02-26 MX MX2012002952A patent/MX2012002952A/es unknown
- 2010-02-26 BR BR112012005401A patent/BR112012005401A2/pt not_active IP Right Cessation
- 2010-02-26 NZ NZ599227A patent/NZ599227A/en not_active IP Right Cessation
- 2010-02-26 KR KR1020167034405A patent/KR20160147061A/ko not_active Application Discontinuation
- 2010-02-26 MY MYPI2012001081A patent/MY162348A/en unknown
-
2012
- 2012-03-06 IL IL218495A patent/IL218495A0/en unknown
- 2012-04-10 CO CO12058149A patent/CO6531434A2/es not_active Application Discontinuation
-
2015
- 2015-02-24 JP JP2015034419A patent/JP6025886B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MY162348A (en) | 2017-06-15 |
| TW201109312A (en) | 2011-03-16 |
| IL218495A0 (en) | 2012-07-31 |
| MX2012002952A (es) | 2012-04-02 |
| JP6025886B2 (ja) | 2016-11-16 |
| CO6531434A2 (es) | 2012-09-28 |
| WO2011030575A1 (ja) | 2011-03-17 |
| SG178938A1 (en) | 2012-04-27 |
| BR112012005401A2 (pt) | 2017-02-21 |
| AU2010293647A1 (en) | 2012-03-29 |
| US20120258971A1 (en) | 2012-10-11 |
| UA108862C2 (uk) | 2015-06-25 |
| KR20120065392A (ko) | 2012-06-20 |
| CA2773253A1 (en) | 2011-03-17 |
| KR20160147061A (ko) | 2016-12-21 |
| JP2015129160A (ja) | 2015-07-16 |
| JPWO2011030575A1 (ja) | 2013-02-04 |
| NZ599227A (en) | 2014-02-28 |
| AU2010293647B2 (en) | 2015-06-25 |
| RU2555760C2 (ru) | 2015-07-10 |
| TWI465442B (zh) | 2014-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2883751A1 (en) | Methods of treating alzheimer's disease and pharmaceutical compositions thereof | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| NZ602510A (en) | Treatment of lupus nephritis using laquinimod | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| NZ605887A (en) | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain | |
| EA201690069A1 (ru) | Применение высоких доз придопидина для лечения болезни хантингтона | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| JP2014516942A5 (ru) | ||
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| EA200700214A1 (ru) | Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией | |
| BR112014015482A8 (pt) | compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática | |
| NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
| RU2015102772A (ru) | Бензодиазелипы для мелкоклеточного рака легкого | |
| NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| JP2015522018A5 (ru) | ||
| MX2011011058A (es) | Antagonistas del receptor ep4 para el tratamiento de cancer. | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| MX2014002480A (es) | Uso del compuesto organico para el tratamiento del sindrome de noonan. | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| RU2015112121A (ru) | Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний | |
| DE602007014193D1 (de) | Behandlung psychiatrischer patienten mit schlafstörungen und/oder übermässiger tagesschläfrigkeit mit paliperidon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20180227 |